Trade Q32 Bio Inc - QTTB CFD

Homology Medicines Company profile

About Homology Medicines Inc

Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).

Latest shares articles

ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
14:15, 16 October 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:41, 11 September 2024
Stocks struggle for direction as US jobs data fails to give assurance
Traders struggle to find a direction as the latest US jobs data gives a mixed picture heading into the FOMC September meeting.
13:32, 6 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
09:13, 29 August 2024

Read our reviews to find out more about us

Read the feedback from our clients around the world.

Very trustworthy and affordable for any size trades

infoaamon

It is very easy to connect with TradingView but the web interface is also great.

remi74

Easy to use and great support. Been using it for 2 years already and still happy

jdancer37

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

DANIEL

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

Yahyaamez

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

Iuliia Salivon

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

Moh ST

-Nice -Easy to use - Beautiful Interface

adenysenko24

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

Daniel

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

John Fallows

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

PHEMELO

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Osondu Paul

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading